Global Gout Market Size to Exceed USD 8.15 Billion by 2035 | CAGR of 10.38%

Global Gout Market Size to Exceed USD 8.15 Billion by 2035

According to a Research Report Published by Decisions Advisors and Consulting, The Global Gout Market Size is expected to Grow from USD 2.75 Billion in 2024 to USD 8.15 Billion by 2035, at a CAGR of 10.38% during the forecast period 2025-2035.  

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the Global Gout Market Size, Share, and COVID-19 Impact Analysis, By Treatment (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, and Others), By Application (Acute Gout, and Chronic Gout), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. Get Detailed Report Description Here: https://www.decisionsadvisors.com/reports/gout-market                 

The gout market pertains to the worldwide healthcare sector dedicated to diagnosing, treating, and managing gout, a persistent inflammatory arthritis resulting from high uric acid levels. Gout is a type of arthritis characterised by the build-up of uric acid crystals in the joints, leading to pain, swelling, and inflammation. The body generates uric acid as it metabolises purines found in numerous foods and beverages. Gout can be extremely agonising and typically occurs abruptly. Individuals suffering from this condition might experience intense joint pain, swelling, redness, ongoing discomfort, limited range of motion, and more. The market is fueled by the increasing acceptance of the arthroscopic technique for managing the illness, as it facilitates the easy removal of uric acid deposits from patients' joints, enhancing functional results. Moreover, the sector is growing owing to the development of new treatments and specific therapies. In spite of the increasing occurrence of gout and advancements in new therapies. Access to patients is limited, especially in developing countries, due to expensive treatment costs and payment challenges, late diagnoses, inadequate treatment, and low awareness among both patients and healthcare professionals, along with safety concerns and side effects associated with existing medications.

The urate-lowering agents segment dominated the market in 2024 and is projected to grow at a significant CAGR over the forecast period.       

Based on the treatment, the gout market is segmented into NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others. Among these, the urate-lowering agents segment dominated the market in 2024 and is projected to grow at a significant CAGR over the forecast period. Medications like febuxostat and allopurinol play a crucial role in treatment guidelines, showing their superiority in the market.

The acute gout segment accounted for the highest market revenue in 2024 and is expected to grow at a significant CAGR during the forecast period.     

Based on the application, the gout market is divided into acute gout and chronic gout. Among these, the acute gout segment accounted for the highest market revenue in 2024 and is expected to grow at a significant CAGR during the forecast period. The quick occurrences of intense pain, swelling, and inflammation primarily impact the big toe and additional joints. This is because of its greater occurrence rate and immediate necessity for treatment.

Asia Pacific is expected to hold the majority share of the global gout market during the forecast period.       

Asia Pacific is expected to hold the majority share of the global gout market during the forecast period. The Asia-Pacific region is emerging as the leading choice for outsourcing manufacturing services, thanks to its skilled workforce, reduced labour expenses, and governmental support for R&D investments to accelerate new product innovation. This results from various factors, such as the rising count of gout sufferers, the advancement of healthcare facilities, and the heightened investments made by major entities alongside local manufacturers

Europe is anticipated to grow at the fastest pace in the global gout market during the forecast period. The availability of advanced diagnostic and treatment facilities, along with the increasing elderly population prone to gout, is driving the demand for effective therapies and treatments, along with escalating healthcare expenses. The Italian gout market is expected to expand at the fastest pace in Europe, followed closely by the UK gout market, due to increased healthcare expenditures that also enhance business activities and governmental programs.

Major vendors in the global gout market are Arrowhead Pharmaceuticals, Inc., AstraZeneca, GSK plc., Hikma Pharmaceuticals plc, Horizon Therapeutics plc, Iroko Pharmaceutical LLC, MERCK & Co. Inc., Mylan N.V., Novartis AG, Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Teva Pharmaceutical Industries Ltd., Zydus Group, and others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development   

• In July 2025, Shanton Pharma’s investigational therapy SAP-001 received FDA Fast Track designation for the treatment of refractory gout. They are targeting patients with hyperuricemia who are unresponsive or intolerant to conventional urate-lowering therapies.

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors and Consulting has segmented the gout market based on the below-mentioned segments: 

Global Gout Market, By Product Type

• NSAIDs
• Corticosteroids
• Colchicine
• Urate-Lowering Agents
• Others

Global Gout Market, By Application

• Acute Gout
• Chronic Gout

Global Gout Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa